The drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.
The evolving recognition of inflammation as a driver of cardiovaacular risk and has led some to speculate around a potential role for colchicine 0.5 mg, which has a PDUFA date in June 2023, for reducing risk in patients with ASCVD.
Our March 2023 cardiology month in review features top headlines from ACC.23, an approval for children with HoFH, and a feature celebrating the 10-year anniversary of the first SGLT2 inhibitor approval.
New evidence released today from a study of 31,245 patients already taking statin therapy indicates that inflammation may be a more powerful predictor of risk of future cardiovascular events-;such as heart attack and stroke -; than "bad" cholesterol.